OverviewSuggest Edit

Galecto Biotech is a company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer, and inflammation. Its products target galectins or galactoside binding lectins, which are a group of proteins shown to be involved in a range of disease processes.
TypePublic
Founded2011
HQKøbenhavn, DK
Websitegalecto.com

Latest Updates

Employees (est.) (Jul 2021)28
Share Price (Oct 2021)$3.4(-3%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Galecto

Amit D. Munshi

Amit D. Munshi

Chairman of the Board
Hans T. Schambye

Hans T. Schambye

CEO
Anders Pedersen

Anders Pedersen

COO
Bertil Lindmark

Bertil Lindmark

CMO
Jonathan Freve

Jonathan Freve

CFO
Garrett Winslow

Garrett Winslow

General Counsel
Show more

Galecto Office Locations

Galecto has an office in København
København, DK (HQ)
Ole Maaløes Vej 3
Show all (1)

Galecto Financials and Metrics

Galecto Revenue

USD

Net income (Q1, 2021)

(13.3m)

EBIT (Q1, 2021)

(13.6m)

Market capitalization (22-Oct-2021)

85.9m

Closing stock price (22-Oct-2021)

3.4

Cash (31-Mar-2021)

74.3m

EV

12.6m
Galecto's current market capitalization is $85.9 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

2.8m2.4m9.0m

R&D expense

10.1m19.7m24.6m

Operating expense total

12.9m39.0m33.6m

EBIT

(12.9m)(39.0m)33.6m
Half Year
USDH1, 2019H1, 2020

General and administrative expense

1.1m2.9m

R&D expense

8.2m9.2m

Operating expense total

9.3m12.2m

EBIT

(9.3m)(12.2m)
Quarterly
USDQ3, 2020Q1, 2021

General and administrative expense

2.5m3.6m

R&D expense

7.7m10.0m

Operating expense total

10.2m13.6m

EBIT

10.2m(13.6m)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

31.0m11.3m163.6m

Prepaid Expenses

5.7m

Current Assets

35.0m56.1m169.3m

Total Assets

35.1m56.6m171.6m
Quarterly
USDQ2, 2020Q3, 2020Q1, 2021

Cash

35.8m85.3m74.3m

Prepaid Expenses

5.3m6.6m

Current Assets

39.4m96.1m116.9m

PP&E

63.0k
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(15.9m)(36.5m)(34.8m)

Accounts Payable

733.0k1.9m(477.0k)

Cash From Operating Activities

(13.7m)(19.3m)(38.2m)

Cash From Investing Activities

(326.0k)
Quarterly
USDQ2, 2019Q2, 2020Q3, 2020Q1, 2021

Net Income

(8.0m)(11.6m)(23.3m)(13.3m)

Depreciation and Amortization

2.0k

Accounts Payable

666.0k(1.6m)1.1m(1.1m)

Cash From Operating Activities

(8.5m)(15.1m)(23.7m)(14.2m)
USDFY, 2018

Financial Leverage

-1 x
Show all financial metrics

Galecto Operating Metrics

Q2, 2020

Phase I/IIa Trials Products

3

Phase IIb Trials Products

1
Show all operating metrics

Galecto Acquisitions / Subsidiaries

Company NameDateDeal Size
Galecto Biotech AB
Galecto Biotech ApS
PharmAkea, Inc.

Galecto Online and Social Media Presence

Embed Graph

Galecto News and Updates

HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology

SINGAPORE, Oct. 20, 2021 /PRNewswire/ -- HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a biotechnology company focused on the development of novel treatments for fibrosis and cancer. This...

Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, the Company’s Chief Executive Officer, will be presenting on Tuesday, Septembe…

Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial)

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. Myelof…

Galecto Reports Second Quarter Operating and Financial Results

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30, 2021.

Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has resumed recruitment in its Phase 2b GALACTIC-1 trial of GB0139 for the treatment of Id…

Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times

Shares of Orphazyme A/S blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility fo…
Show more

Galecto Frequently Asked Questions

  • When was Galecto founded?

    Galecto was founded in 2011.

  • Who are Galecto key executives?

    Galecto's key executives are Amit D. Munshi, Hans T. Schambye and Anders Pedersen.

  • How many employees does Galecto have?

    Galecto has 28 employees.

  • Who are Galecto competitors?

    Competitors of Galecto include Metabomed, Supernus Pharmaceuticals and ITeos Therapeutics.

  • Where is Galecto headquarters?

    Galecto headquarters is located at Ole Maaløes Vej 3, København.

  • Where are Galecto offices?

    Galecto has an office in København.

  • How many offices does Galecto have?

    Galecto has 1 office.